Free Biopharma Daily Stock Updates - 07/20/21

$XBI $129.1 +2.3%

---

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

---

Covid Updates

$IMNM +9.0% Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing. source

$MRNA -2.0% Moderna Partners with Takeda and the Government of Japan to Supply Additional 50 Million Doses of Moderna’s COVID-19 Vaccine and Variant Booster Vaccine Candidate in 2022. source

Pipeline Updates

$CYAD +2.7% Celyad Oncology Presents Updates on Allogeneic CAR T Clinical Candidates and shRNA-based Preclinical Concepts at Research & Development Day. source

$SRNE +1.8% Sorrento Therapeutics Announces the Formation of Sorrento Therapeutics Mexico for Commercialization of COVI-STIX and Development of Sorrento’s Portfolio of COVID-19 Products in Mexico and Parts of Latin America. source

$ALBO -4.6% Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Familial Intrahepatic Cholestasis (PFIC). source

$LUMO -2.7% Lumos Pharma Announces Clinical Updates. source

$SESN -1.8% Sesen Bio and Qilu Pharmaceutical Announce Enrollment of First Patient in Clinical Trial for Vicineum™ in China. source

$SRNE +1.8% Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter. source

$ANVS +0.7% Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer’s Study. source

$ZSAN +0.1% Zosano Pharma Announces Issuance of U.S. Patent for Method of Rapidly Achieving Therapeutic Levels with M207 for the Acute Treatment of Migraine. source

$RLMD -0.9% Relmada Therapeutics Announces the Acquisition of Development and Commercial Rights to Novel Psilocybin and Derivates Program from Arbormentis LLC. source

$LCTX +3.9% OpRegen® Clinical Data Continues to Demonstrate Functional and Anatomical Improvements in Patients With Dry AMD With Geographic Atrophy. source

$WVE +6.4% Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a FOCUS-C9 Clinical Trial of WVE-004 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. source

$ALDX +0.9% Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Primary Vitreoretinal Lymphoma. source

$SWTX +7.7% SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041. source

$RDHL +10.9% RedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx. source

$ADMA +1.9% ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection. https://www.admabiologics.com/investors/press-releases/detail/503/adma-biologics-announces-successful-completion-of-fda

$MDWD -2.0% MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns. source

$EYPT +8.5% EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®.

$LTRN +17.2% Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184. source

$MYOV +0.8% Myovant Sciences Announces European Commission Approval for RYEQO® for the Treatment of Women With Uterine Fibroids. source

$ARDX -73.9% Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis. source

$PLXP +18.4% On 7/19 PLx Pharma Inc.’s VAZALORE to Launch in over 8,000 Walgreens Stores Nationwide in August. source

$CYDY +14.1% CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials. source

Financial Updates

$ENDP +24.7% On 7/15 Endo Comments on Tennessee Appeals Court Orders. source

---

Posted by FS